Javascript must be enabled to continue!
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach
View through CrossRef
Objetive:
Cardiac ischemia related myocardial damage has been considered as a major reason of heart failure. We aimed to investigate the role of levosimendan (LEVO) in comparison to ramipril and sacubitril/valsartan (Sac/Val) in preventing the damage associated to isoproterenol (ISO) induced myocardial infarction.
Method:
Myocardial infarction was induced by injecting subcutaneous isoproterenol (5 mg/kg once for 7 consecutive days) to establish experimental heart failure model. Simultaneously, LEVO (1 mg/kg/day), ramipril (3mg/kg/day) and Sac/Val (68 mg/kg/day) suspension were administered orally for four weeks.
Results:
We observed a significant correlation between ISO induced ischemia with cardiac remodeling and alterations in myocardial architecture. LEVO, ramipril, and Sac/Val significantly prevented lipid peroxidation, damage of antioxidant enzymes like superoxide dismutase, catalase, glutathione and thioredoxin reductase. We also observed their ameliorative effects in cardiac hypertrophy of myocardium evidenced by reduced heart weight to body weight ratio and transforming growth factor β related collagen deposition. LEVO, ramipril, and Sac/Val also maintained cardiac biomarkers like lactate dehydrogenase, creatine kinase-MB, brain natriuretic peptide and cardiac Troponin-I indicating reduced myocardial damage that further demonstrated by histopathological examination. Decreased sarcoplasmic endoplasmic reticulum Ca2+ATPase2a and sodium-calcium exchanger-1 protein depletion after LEVO, ramipril, and Sac/Val adminisreration indicated improved Ca2+ homeostasis during myocardial contractility.
Conclusion:
Our findings suggest that LEVO have comparable effects to ramipril, and Sac/Val in preventing myocardial damage via balancing oxidant-antioxidant system, decreased collagen deposition, reduced myocardial stress as well as improved Ca2+ homeostasis during myocardial contractility.
Title: Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/
Valsartan in Isoproterenol-induced Experimental Heart Failure: A
Hemodynamic and Molecular Approach
Description:
Objetive:
Cardiac ischemia related myocardial damage has been considered as a major reason of heart failure.
We aimed to investigate the role of levosimendan (LEVO) in comparison to ramipril and sacubitril/valsartan (Sac/Val) in preventing the damage associated to isoproterenol (ISO) induced myocardial infarction.
Method:
Myocardial infarction was induced by injecting subcutaneous isoproterenol (5 mg/kg once for 7 consecutive days) to establish experimental heart failure model.
Simultaneously, LEVO (1 mg/kg/day), ramipril (3mg/kg/day) and Sac/Val (68 mg/kg/day) suspension were administered orally for four weeks.
Results:
We observed a significant correlation between ISO induced ischemia with cardiac remodeling and alterations in myocardial architecture.
LEVO, ramipril, and Sac/Val significantly prevented lipid peroxidation, damage of antioxidant enzymes like superoxide dismutase, catalase, glutathione and thioredoxin reductase.
We also observed their ameliorative effects in cardiac hypertrophy of myocardium evidenced by reduced heart weight to body weight ratio and transforming growth factor β related collagen deposition.
LEVO, ramipril, and Sac/Val also maintained cardiac biomarkers like lactate dehydrogenase, creatine kinase-MB, brain natriuretic peptide and cardiac Troponin-I indicating reduced myocardial damage that further demonstrated by histopathological examination.
Decreased sarcoplasmic endoplasmic reticulum Ca2+ATPase2a and sodium-calcium exchanger-1 protein depletion after LEVO, ramipril, and Sac/Val adminisreration indicated improved Ca2+ homeostasis during myocardial contractility.
Conclusion:
Our findings suggest that LEVO have comparable effects to ramipril, and Sac/Val in preventing myocardial damage via balancing oxidant-antioxidant system, decreased collagen deposition, reduced myocardial stress as well as improved Ca2+ homeostasis during myocardial contractility.
Related Results
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Efficacy and safety of vericiguat in patients with HFrEF treated with sacubitril/valsartan: results from the VICTORIA trial
Abstract
Background
In the VICTORIA trial (n=5050) the reduction in the primary composite endpoint of cardiovascular death (CVD)...
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
Comparative and Combinatorial Effects of Resveratrol and Sacubitril/Valsartan alongside Valsartan on Cardiac Remodeling and Dysfunction in MI-Induced Rats
The development and progression of heart failure (HF) due to myocardial infarction (MI) is a major concern even with current optimal therapy. Resveratrol is a plant polyphenol with...
Effect of Levosimendan on the short-term clinical efficacy of patients with acute decompensated heart failure
Effect of Levosimendan on the short-term clinical efficacy of patients with acute decompensated heart failure
OBJECTIVE To observe the effect of levosimendan on the clinical efficacy of patients with acute decompensated heart failure (ADHF). METHODS Collected 124 patients with acute decom...
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Kajian Literatur Profil Farmakokinetika Sacubitril-Valsartan Pada Subjek Sehat dan Gagal Jantung
Abstract. Sacubitril-Valsartan is a first-class therapeutic agent for ARNI (Angiotensin Receptor-Neprilysin Inhibitor) which can reduce blood pressure and reduce mortality and morb...
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients
Evaluation of Sacubitril/Valsartan Initiation in Outpatient Heart Failure Patients
Abstract:
Despite sacubitril/valsartan being on the market since 2015, clinicians are still determining the best way to initiate therapy to optimize outcomes and minimize...
Sacubitil/valsartan in systemic right ventricular failure
Sacubitil/valsartan in systemic right ventricular failure
Abstract
Background
In patients with heart failure with low ejection fraction (EF) (≤35%) sacubitril/valsartan is proven to be b...
A New Mechanism of Action in Heart Failure
A New Mechanism of Action in Heart Failure
Objective: To evaluate the efficacy, safety, and clinical significance of sacubitril/valsartan (Entresto) in patients with heart failure with a reduced ejection fraction (HFrEF). D...
Abstract 14627: Angiotensin-Neprilysin Inhibition in Cardiac Sarcoidosis
Abstract 14627: Angiotensin-Neprilysin Inhibition in Cardiac Sarcoidosis
Introduction:
Sacubitril/Valsartan is an established treatment for heart failure patients with reduced ejection fraction (HFrEF). However, there is a paucity of data on...

